{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:22:37Z","timestamp":1790338957453,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ymthe.2019.07.019","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T19:26:25Z","timestamp":1565033185000},"page":"1906-1918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1\/CD137L Subverts the Suppression of CD8+ T Cells in HCC"],"prefix":"10.1016","volume":"27","author":[{"given":"Yonghui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.07.019_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T\u00a0cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41417-018-0042-1","article-title":"Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference","volume":"26","author":"Dyer","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2019.07.019_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.07.019_bib4","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2019.07.019_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2019.07.019_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.07.019_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2019.07.019_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2019.07.019_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/eji.201445388","article-title":"Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy","volume":"46","author":"Sanchez-Paulete","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1084\/jem.181.3.985","article-title":"Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP","volume":"181","author":"DeBenedette","year":"1995","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-2478(94)00227-I","article-title":"Characterization of human homologue of 4-1BB and its ligand","volume":"45","author":"Zhou","year":"1995","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2019.07.019_bib15","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.4049\/jimmunol.169.9.4882","article-title":"4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1","volume":"169","author":"Lee","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib16","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1073\/pnas.1506357112","article-title":"Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb","volume":"112","author":"Weigelin","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.07.019_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.07.019_bib18","doi-asserted-by":"crossref","first-page":"e1371896","DOI":"10.1080\/2162402X.2017.1371896","article-title":"Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications","volume":"6","author":"Cabo","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2019.07.019_bib19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.07.019_bib20","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2019.07.019_bib21","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2019.07.019_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib23","doi-asserted-by":"crossref","first-page":"e1376156","DOI":"10.1080\/2162402X.2017.1376156","article-title":"Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy","volume":"7","author":"Yan","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2019.07.019_bib24","first-page":"129","article-title":"Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor","volume":"35","author":"Shindo","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ymthe.2019.07.019_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gt.2016.70","article-title":"Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy","volume":"24","author":"Ilett","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2019.07.019_bib26","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1172\/JCI125039","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.07.019_bib27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.019_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cyto.a.20594","article-title":"Use of CD137 to study the full repertoire of CD8+ T\u00a0cells without the need to know epitope specificities","volume":"73","author":"W\u00f6lfl","year":"2008","journal-title":"Cytometry A"},{"key":"10.1016\/j.ymthe.2019.07.019_bib30","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.07.019_bib31","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2019.07.019_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4251\/wjgo.v2.i11.399","article-title":"Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer","volume":"2","author":"Liu","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T\u00a0cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2019.07.019_bib34","doi-asserted-by":"crossref","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2019.07.019_bib35","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.07.019_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-pd-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.019_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2019.07.019_bib38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.gt.3302556","article-title":"The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma","volume":"12","author":"Xu","year":"2005","journal-title":"Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619303582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619303582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:57Z","timestamp":1761501357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619303582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1525001619303582"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1\/CD137L Subverts the Suppression of CD8+ T Cells in HCC","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}